Isopentaquine is a synthetic antimalarial drug that was initially developed in the 1960s. It is a member of the 4-aminoquinoline class of antimalarials, which also includes chloroquine and amodiaquine. Isopentaquine is a potent inhibitor of the parasite's heme polymerase enzyme, which is essential for the parasite's survival. In preclinical studies, isopentaquine has demonstrated activity against both chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum, the most deadly species of malaria parasite. Its long half-life and the ability to be dosed once monthly make it particularly attractive for treatment and prevention. Isopentaquine is currently being studied in clinical trials as a potential treatment for malaria. Researchers are exploring its potential use in combination therapies, as well as its potential for the development of new, more effective antimalarial drugs.'
ID Source | ID |
---|---|
PubMed CID | 98196 |
CHEMBL ID | 480978 |
MeSH ID | M0065623 |
Synonym |
---|
isopentaquine |
s. n. 13274 |
quinoline, 8-[[4-(isopropylamino)-1-methylbutyl]amino]-6-methoxy- |
nsc88372 |
nsc-88372 |
529-73-7 |
1, n4-(6-methoxy-8-quinolinyl)-n1-(1-methylethyl)- |
sn 13,274 |
8-(4-(isopropylamino)-1-methylbutylamino)-6-methoxyquinoline |
4-n-(6-methoxyquinolin-8-yl)-1-n-propan-2-ylpentane-1,4-diamine |
CHEMBL480978 |
n(4)-(6-methoxy-8-quinolinyl)- n(1)-(1-methylethyl)-1,4-pentanediamine |
quinoline, 8-((4-(isopropylamino)-1-methylbutyl)amino)-6-methoxy- |
1,4-pentanediamine, n4-(6-methoxy-8-quinolinyl)-n1-(1-methylethyl)- |
nsc 88372 |
n4-(6-methoxyquinolin-8-yl)-n1-propan-2-yl-pentane-1,4-diamine |
n4-(6-methoxy-8-quinolinyl)-n1-propan-2-ylpentane-1,4-diamine |
cid_98196 |
isopropyl-[4-[(6-methoxy-8-quinolyl)amino]pentyl]amine |
bdbm40743 |
n1-isopropyl-n4-(6-methoxyquinolin-8-yl)pentane-1,4-diamine |
STARBLD0008137 |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
90-kda heat shock protein beta HSP90 beta, partial | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.1736 | 9.8032 | 29.2701 | AID754 |
heat shock protein HSP 90-alpha isoform 2 | Homo sapiens (human) | IC50 (µMol) | 50.0000 | 0.1736 | 9.8032 | 29.2701 | AID754 |
Heat shock protein HSP 90-alpha | Homo sapiens (human) | IC50 (µMol) | 14.4000 | 0.0004 | 0.6950 | 10.0000 | AID339641 |
Heat shock protein HSP 90-beta | Homo sapiens (human) | IC50 (µMol) | 14.4000 | 0.0010 | 0.6836 | 10.0000 | AID339641 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID339642 | Inhibition of Hsp90 in human MCF7 cells assessed as Her2 level after 24 hrs by Western blot | 2008 | Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14 | Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling. |
AID339641 | Inhibition of Hsp90 in human MCF7 cell lysates assessed as interaction with Cy3b-conjugated geldanamycin by FP assay | 2008 | Bioorganic & medicinal chemistry, Jul-15, Volume: 16, Issue:14 | Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 3 (60.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (21.67) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 6 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |